UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know

UBS has decided to maintain its Buy rating of CymaBay Therapeutics CBAY and raise its price target from $18.00 to $25.00.

Shares of CymaBay Therapeutics are trading up 7.26% over the last 24 hours, at $15.36 per share.

A move to $25.00 would account for a 62.76% increase from the current share price.

About CymaBay Therapeutics

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.